Daily desk

News

Artificial intelligence, technology, science, health and education — reported daily, with the original source attached to every item.

2 stories

Two experimental drugs, an oral pill and an IV nanoparticle, approach the smooth, pocket-less surface of the KRAS G12D protein, alongside the trials' headline response rates.

Latest 🩺 Health

Two Independent Trials Report Responses in KRAS G12D Cancers, but Nature Medicine Editorial Urges Caution

Two Nature Medicine trials of oral and intravenous KRAS G12D inhibitors report response rates of 41% and 63.3% in advanced solid tumors and pancreatic cancer, but an accompanying editorial calls the results a start, not a settled breakthrough.

EduFabTech · 1h ago · 5 min read

Split cards contrast PATHFINDER 2's 60.3% positive predictive value against NHS-Galleri's missed primary endpoint, framed as "two trials, one blood test, different verdicts."

🩺 Health Study

Two Nature Medicine Trials of a Multi-Cancer Blood Test Reach Different Verdicts on the Same Day

Published the same day in Nature Medicine, PATHFINDER 2 and the NHS-Galleri trial reach different verdicts on GRAIL's Galleri blood test: s…

EduFabTech · 7h ago · 5 min read